FDA Grants Orphan Drug Status to HUTCHMED's Sovleplenib for Rare Anemia

HUTCHMED's investigational drug, sovleplenib, has received Orphan Drug Designation from the FDA for treating autoimmune hemolytic anemia (AIHA). This marks the second such designation for the SYK inhibitor, following one for primary immune thrombocytopenia. The designation provides incentives like potential market exclusivity, accelerating development for this rare disease and potentially offering new treatment options for patients.